DxS Announces License Agreement with Wellcome Trust to expand their range of companion diagnostics

04-Sep-2008 - United Kingdom

DxS has signed a non-exclusive global licensing agreement with the Wellcome Trust. DxS will provide a research test for use in clinical trials to detect the presence of the V600E B-RAF mutation, which is found in melanomas, lung and thyroid cancers. The V600E B-RAF mutation was identified by scientists at the Wellcome Trust and can be found in around 36% to 40% of skin and thyroid cancers and up to 13% of cancers in the large intestine.

Researchers will use the test to determine a patient’s cancer mutation status, which may predict how they respond to cancer therapies. If clinical trials are successful, this could lead to a companion diagnostics to predict response for novel cancer therapies for skin, thyroid and large intestine cancers.

Dr. Stephen Little, CEO of DxS Ltd., said: “With many novel drugs in development for skin, thyroid and colon cancer the potential for this assay is enormous. Through this licensing agreement, we plan to expand the range of biomarker tests to our customers, aiding the treatment of a number of types of cancer.”

Financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures